Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.
Identifieur interne : 002F42 ( PubMed/Curation ); précédent : 002F41; suivant : 002F43Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.
Auteurs : Stefan Zeuzem [Allemagne] ; Vicente Soriano [Espagne] ; Tarik Asselah [France] ; Edward J. Gane [Nouvelle-Zélande] ; Jean-Pierre Bronowicki [France] ; Peter Angus [Australie] ; Ansgar W. Lohse [Allemagne] ; Felix Stickel [Suisse] ; Beat Müllhaupt [Suisse] ; Stuart Roberts [Australie] ; Marcus Schuchmann [Allemagne] ; Michael Manns [Allemagne] ; Marc Bourlière [France] ; Maria Buti [Espagne] ; Jerry O. Stern [États-Unis] ; John-Paul Gallivan [Allemagne] ; Florian Voss [Allemagne] ; John P. Sabo [États-Unis] ; Wulf Böcher [Allemagne] ; Federico J. Mensa [États-Unis]Source :
- Antimicrobial agents and chemotherapy [ 1098-6596 ] ; 2015.
Descripteurs français
- KwdFr :
- Acrylates (effets indésirables), Acrylates (usage thérapeutique), Adulte, Adulte d'âge moyen, Antiviraux (effets indésirables), Antiviraux (usage thérapeutique), Benzimidazoles (effets indésirables), Benzimidazoles (usage thérapeutique), Cirrhose du foie (), Cirrhose du foie (traitement médicamenteux), Femelle, Humains, Hépatite C chronique (), Hépatite C chronique (traitement médicamenteux), Jeune adulte, Mâle, Oligopeptides (effets indésirables), Oligopeptides (usage thérapeutique), Ribavirine (effets indésirables), Ribavirine (usage thérapeutique), Sujet âgé, Sujet âgé de 80 ans ou plus, Thiazoles (effets indésirables), Thiazoles (usage thérapeutique).
- MESH :
- effets indésirables : Acrylates, Antiviraux, Benzimidazoles, Oligopeptides, Ribavirine, Thiazoles.
- traitement médicamenteux : Cirrhose du foie, Hépatite C chronique.
- usage thérapeutique : Acrylates, Antiviraux, Benzimidazoles, Oligopeptides, Ribavirine, Thiazoles.
- Adulte, Adulte d'âge moyen, Cirrhose du foie, Femelle, Humains, Hépatite C chronique, Jeune adulte, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- Acrylates (adverse effects), Acrylates (therapeutic use), Adult, Aged, Aged, 80 and over, Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Benzimidazoles (adverse effects), Benzimidazoles (therapeutic use), Female, Hepatitis C, Chronic (complications), Hepatitis C, Chronic (drug therapy), Humans, Liver Cirrhosis (complications), Liver Cirrhosis (drug therapy), Male, Middle Aged, Oligopeptides (adverse effects), Oligopeptides (therapeutic use), Ribavirin (adverse effects), Ribavirin (therapeutic use), Thiazoles (adverse effects), Thiazoles (therapeutic use), Young Adult.
- MESH :
- chemical , adverse effects : Acrylates, Antiviral Agents, Benzimidazoles, Oligopeptides, Ribavirin, Thiazoles.
- chemical , therapeutic use : Acrylates, Antiviral Agents, Benzimidazoles, Oligopeptides, Ribavirin, Thiazoles.
- complications : Hepatitis C, Chronic, Liver Cirrhosis.
- drug therapy : Hepatitis C, Chronic, Liver Cirrhosis.
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Young Adult.
Abstract
Patients with advanced hepatic fibrosis or cirrhosis with chronic hepatitis C virus (HCV) infection represent an unmet need. The HCV NS3/4A inhibitor, faldaprevir, was evaluated in combination with the nonnucleoside NS5B inhibitor, deleobuvir, with or without ribavirin in treatment-naive patients with HCV genotype 1 infection in the SOUND-C2 study. Here, the efficacy and safety of this interferon-free regimen in a subset of patients with advanced liver fibrosis, including those with compensated cirrhosis, were assessed. Patients (n=362) were randomized to once-daily faldaprevir with either twice-daily (BID) or three-times-daily (TID) deleobuvir for 16 (TID16W), 28 (TID28W and BID28W), or 40 (TID40W) weeks with or without ribavirin (TID28W-NR). Patients were classified according to fibrosis stage (F0 to F2 versus F3 to F4) and the presence of cirrhosis (yes/no). In total, 85 (24%) patients had advanced fibrosis/cirrhosis (F3 to F4) and 33 (9%) had cirrhosis. Within each treatment arm, differences in rates of sustained virologic response 12 weeks after completion of treatment (SVR12) between patients with mild to moderate fibrosis (F0 to F2) versus F3 to F4 did not show a consistent pattern and were not statistically significant (63% versus 47% for TID16W, 53% versus 76% for TID28W, 48% versus 67% for TID40W, 70% versus 67% for BID28W, and 40% versus 36% for TID28W-NR, respectively; P > 0.05 for each arm). The most frequent adverse events in patients with/without cirrhosis were gastrointestinal and skin events, which were mostly mild or moderate in intensity. The degree of liver fibrosis did not appear to affect the probability of achieving SVR12 following treatment with the interferon-free regimen of faldaprevir, deleobuvir, and ribavirin. (This study has been registered at ClinicalTrials.gov under registration no. NCT01132313.).
DOI: 10.1128/AAC.04383-14
PubMed: 25512403
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003023
Links to Exploration step
pubmed:25512403Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.</title><author><name sortKey="Zeuzem, Stefan" sort="Zeuzem, Stefan" uniqKey="Zeuzem S" first="Stefan" last="Zeuzem">Stefan Zeuzem</name><affiliation wicri:level="1"><nlm:affiliation>J. W. Goethe University Hospital, Frankfurt, Germany zeuzem@em.uni-frankfurt.de.</nlm:affiliation><country wicri:rule="url">Allemagne</country><wicri:regionArea>J. W. Goethe University Hospital, Frankfurt</wicri:regionArea></affiliation></author><author><name sortKey="Soriano, Vicente" sort="Soriano, Vicente" uniqKey="Soriano V" first="Vicente" last="Soriano">Vicente Soriano</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Carlos III, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Carlos III, Madrid</wicri:regionArea></affiliation></author><author><name sortKey="Asselah, Tarik" sort="Asselah, Tarik" uniqKey="Asselah T" first="Tarik" last="Asselah">Tarik Asselah</name><affiliation wicri:level="1"><nlm:affiliation>Service d'Hépatologie, Hôpital Beaujon, INSERM UMR S 1149, CRI, Université Paris Diderot, DHU UNITY, Clichy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Hépatologie, Hôpital Beaujon, INSERM UMR S 1149, CRI, Université Paris Diderot, DHU UNITY, Clichy</wicri:regionArea></affiliation></author><author><name sortKey="Gane, Edward J" sort="Gane, Edward J" uniqKey="Gane E" first="Edward J" last="Gane">Edward J. Gane</name><affiliation wicri:level="1"><nlm:affiliation>Auckland Clinical Studies, Auckland, New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Auckland Clinical Studies, Auckland</wicri:regionArea></affiliation></author><author><name sortKey="Bronowicki, Jean Pierre" sort="Bronowicki, Jean Pierre" uniqKey="Bronowicki J" first="Jean-Pierre" last="Bronowicki">Jean-Pierre Bronowicki</name><affiliation wicri:level="1"><nlm:affiliation>INSERM 954, Centre Hospitalier Universitaire de Nancy, Vandoeuvre les Nancy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM 954, Centre Hospitalier Universitaire de Nancy, Vandoeuvre les Nancy</wicri:regionArea></affiliation></author><author><name sortKey="Angus, Peter" sort="Angus, Peter" uniqKey="Angus P" first="Peter" last="Angus">Peter Angus</name><affiliation wicri:level="1"><nlm:affiliation>Austin Health, Heidelberg, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Austin Health, Heidelberg</wicri:regionArea></affiliation></author><author><name sortKey="Lohse, Ansgar W" sort="Lohse, Ansgar W" uniqKey="Lohse A" first="Ansgar W" last="Lohse">Ansgar W. Lohse</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital Hamburg-Eppendorf, Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University Hospital Hamburg-Eppendorf, Hamburg</wicri:regionArea></affiliation></author><author><name sortKey="Stickel, Felix" sort="Stickel, Felix" uniqKey="Stickel F" first="Felix" last="Stickel">Felix Stickel</name><affiliation wicri:level="1"><nlm:affiliation>University of Bern, Bern, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>University of Bern, Bern</wicri:regionArea></affiliation></author><author><name sortKey="Mullhaupt, Beat" sort="Mullhaupt, Beat" uniqKey="Mullhaupt B" first="Beat" last="Müllhaupt">Beat Müllhaupt</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital of Zurich, Zurich, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>University Hospital of Zurich, Zurich</wicri:regionArea></affiliation></author><author><name sortKey="Roberts, Stuart" sort="Roberts, Stuart" uniqKey="Roberts S" first="Stuart" last="Roberts">Stuart Roberts</name><affiliation wicri:level="1"><nlm:affiliation>Alfred Hospital, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Alfred Hospital, Melbourne</wicri:regionArea></affiliation></author><author><name sortKey="Schuchmann, Marcus" sort="Schuchmann, Marcus" uniqKey="Schuchmann M" first="Marcus" last="Schuchmann">Marcus Schuchmann</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital Mainz, Mainz, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University Hospital Mainz, Mainz</wicri:regionArea></affiliation></author><author><name sortKey="Manns, Michael" sort="Manns, Michael" uniqKey="Manns M" first="Michael" last="Manns">Michael Manns</name><affiliation wicri:level="1"><nlm:affiliation>Medical School of Hannover, Hannover, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Medical School of Hannover, Hannover</wicri:regionArea></affiliation></author><author><name sortKey="Bourliere, Marc" sort="Bourliere, Marc" uniqKey="Bourliere M" first="Marc" last="Bourlière">Marc Bourlière</name><affiliation wicri:level="1"><nlm:affiliation>Hôpital Saint Joseph, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Saint Joseph, Marseille</wicri:regionArea></affiliation></author><author><name sortKey="Buti, Maria" sort="Buti, Maria" uniqKey="Buti M" first="Maria" last="Buti">Maria Buti</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Stern, Jerry O" sort="Stern, Jerry O" uniqKey="Stern J" first="Jerry O" last="Stern">Jerry O. Stern</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut</wicri:regionArea></affiliation></author><author><name sortKey="Gallivan, John Paul" sort="Gallivan, John Paul" uniqKey="Gallivan J" first="John-Paul" last="Gallivan">John-Paul Gallivan</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim</wicri:regionArea></affiliation></author><author><name sortKey="Voss, Florian" sort="Voss, Florian" uniqKey="Voss F" first="Florian" last="Voss">Florian Voss</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim</wicri:regionArea></affiliation></author><author><name sortKey="Sabo, John P" sort="Sabo, John P" uniqKey="Sabo J" first="John P" last="Sabo">John P. Sabo</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut</wicri:regionArea></affiliation></author><author><name sortKey="Bocher, Wulf" sort="Bocher, Wulf" uniqKey="Bocher W" first="Wulf" last="Böcher">Wulf Böcher</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim</wicri:regionArea></affiliation></author><author><name sortKey="Mensa, Federico J" sort="Mensa, Federico J" uniqKey="Mensa F" first="Federico J" last="Mensa">Federico J. Mensa</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25512403</idno><idno type="pmid">25512403</idno><idno type="doi">10.1128/AAC.04383-14</idno><idno type="wicri:Area/PubMed/Corpus">003023</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003023</idno><idno type="wicri:Area/PubMed/Curation">002F42</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002F42</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.</title><author><name sortKey="Zeuzem, Stefan" sort="Zeuzem, Stefan" uniqKey="Zeuzem S" first="Stefan" last="Zeuzem">Stefan Zeuzem</name><affiliation wicri:level="1"><nlm:affiliation>J. W. Goethe University Hospital, Frankfurt, Germany zeuzem@em.uni-frankfurt.de.</nlm:affiliation><country wicri:rule="url">Allemagne</country><wicri:regionArea>J. W. Goethe University Hospital, Frankfurt</wicri:regionArea></affiliation></author><author><name sortKey="Soriano, Vicente" sort="Soriano, Vicente" uniqKey="Soriano V" first="Vicente" last="Soriano">Vicente Soriano</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Carlos III, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Carlos III, Madrid</wicri:regionArea></affiliation></author><author><name sortKey="Asselah, Tarik" sort="Asselah, Tarik" uniqKey="Asselah T" first="Tarik" last="Asselah">Tarik Asselah</name><affiliation wicri:level="1"><nlm:affiliation>Service d'Hépatologie, Hôpital Beaujon, INSERM UMR S 1149, CRI, Université Paris Diderot, DHU UNITY, Clichy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Hépatologie, Hôpital Beaujon, INSERM UMR S 1149, CRI, Université Paris Diderot, DHU UNITY, Clichy</wicri:regionArea></affiliation></author><author><name sortKey="Gane, Edward J" sort="Gane, Edward J" uniqKey="Gane E" first="Edward J" last="Gane">Edward J. Gane</name><affiliation wicri:level="1"><nlm:affiliation>Auckland Clinical Studies, Auckland, New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Auckland Clinical Studies, Auckland</wicri:regionArea></affiliation></author><author><name sortKey="Bronowicki, Jean Pierre" sort="Bronowicki, Jean Pierre" uniqKey="Bronowicki J" first="Jean-Pierre" last="Bronowicki">Jean-Pierre Bronowicki</name><affiliation wicri:level="1"><nlm:affiliation>INSERM 954, Centre Hospitalier Universitaire de Nancy, Vandoeuvre les Nancy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM 954, Centre Hospitalier Universitaire de Nancy, Vandoeuvre les Nancy</wicri:regionArea></affiliation></author><author><name sortKey="Angus, Peter" sort="Angus, Peter" uniqKey="Angus P" first="Peter" last="Angus">Peter Angus</name><affiliation wicri:level="1"><nlm:affiliation>Austin Health, Heidelberg, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Austin Health, Heidelberg</wicri:regionArea></affiliation></author><author><name sortKey="Lohse, Ansgar W" sort="Lohse, Ansgar W" uniqKey="Lohse A" first="Ansgar W" last="Lohse">Ansgar W. Lohse</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital Hamburg-Eppendorf, Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University Hospital Hamburg-Eppendorf, Hamburg</wicri:regionArea></affiliation></author><author><name sortKey="Stickel, Felix" sort="Stickel, Felix" uniqKey="Stickel F" first="Felix" last="Stickel">Felix Stickel</name><affiliation wicri:level="1"><nlm:affiliation>University of Bern, Bern, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>University of Bern, Bern</wicri:regionArea></affiliation></author><author><name sortKey="Mullhaupt, Beat" sort="Mullhaupt, Beat" uniqKey="Mullhaupt B" first="Beat" last="Müllhaupt">Beat Müllhaupt</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital of Zurich, Zurich, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>University Hospital of Zurich, Zurich</wicri:regionArea></affiliation></author><author><name sortKey="Roberts, Stuart" sort="Roberts, Stuart" uniqKey="Roberts S" first="Stuart" last="Roberts">Stuart Roberts</name><affiliation wicri:level="1"><nlm:affiliation>Alfred Hospital, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Alfred Hospital, Melbourne</wicri:regionArea></affiliation></author><author><name sortKey="Schuchmann, Marcus" sort="Schuchmann, Marcus" uniqKey="Schuchmann M" first="Marcus" last="Schuchmann">Marcus Schuchmann</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital Mainz, Mainz, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University Hospital Mainz, Mainz</wicri:regionArea></affiliation></author><author><name sortKey="Manns, Michael" sort="Manns, Michael" uniqKey="Manns M" first="Michael" last="Manns">Michael Manns</name><affiliation wicri:level="1"><nlm:affiliation>Medical School of Hannover, Hannover, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Medical School of Hannover, Hannover</wicri:regionArea></affiliation></author><author><name sortKey="Bourliere, Marc" sort="Bourliere, Marc" uniqKey="Bourliere M" first="Marc" last="Bourlière">Marc Bourlière</name><affiliation wicri:level="1"><nlm:affiliation>Hôpital Saint Joseph, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Saint Joseph, Marseille</wicri:regionArea></affiliation></author><author><name sortKey="Buti, Maria" sort="Buti, Maria" uniqKey="Buti M" first="Maria" last="Buti">Maria Buti</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Stern, Jerry O" sort="Stern, Jerry O" uniqKey="Stern J" first="Jerry O" last="Stern">Jerry O. Stern</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut</wicri:regionArea></affiliation></author><author><name sortKey="Gallivan, John Paul" sort="Gallivan, John Paul" uniqKey="Gallivan J" first="John-Paul" last="Gallivan">John-Paul Gallivan</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim</wicri:regionArea></affiliation></author><author><name sortKey="Voss, Florian" sort="Voss, Florian" uniqKey="Voss F" first="Florian" last="Voss">Florian Voss</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim</wicri:regionArea></affiliation></author><author><name sortKey="Sabo, John P" sort="Sabo, John P" uniqKey="Sabo J" first="John P" last="Sabo">John P. Sabo</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut</wicri:regionArea></affiliation></author><author><name sortKey="Bocher, Wulf" sort="Bocher, Wulf" uniqKey="Bocher W" first="Wulf" last="Böcher">Wulf Böcher</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim</wicri:regionArea></affiliation></author><author><name sortKey="Mensa, Federico J" sort="Mensa, Federico J" uniqKey="Mensa F" first="Federico J" last="Mensa">Federico J. Mensa</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut</wicri:regionArea></affiliation></author></analytic><series><title level="j">Antimicrobial agents and chemotherapy</title><idno type="eISSN">1098-6596</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acrylates (adverse effects)</term><term>Acrylates (therapeutic use)</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (therapeutic use)</term><term>Benzimidazoles (adverse effects)</term><term>Benzimidazoles (therapeutic use)</term><term>Female</term><term>Hepatitis C, Chronic (complications)</term><term>Hepatitis C, Chronic (drug therapy)</term><term>Humans</term><term>Liver Cirrhosis (complications)</term><term>Liver Cirrhosis (drug therapy)</term><term>Male</term><term>Middle Aged</term><term>Oligopeptides (adverse effects)</term><term>Oligopeptides (therapeutic use)</term><term>Ribavirin (adverse effects)</term><term>Ribavirin (therapeutic use)</term><term>Thiazoles (adverse effects)</term><term>Thiazoles (therapeutic use)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acrylates (effets indésirables)</term><term>Acrylates (usage thérapeutique)</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antiviraux (effets indésirables)</term><term>Antiviraux (usage thérapeutique)</term><term>Benzimidazoles (effets indésirables)</term><term>Benzimidazoles (usage thérapeutique)</term><term>Cirrhose du foie ()</term><term>Cirrhose du foie (traitement médicamenteux)</term><term>Femelle</term><term>Humains</term><term>Hépatite C chronique ()</term><term>Hépatite C chronique (traitement médicamenteux)</term><term>Jeune adulte</term><term>Mâle</term><term>Oligopeptides (effets indésirables)</term><term>Oligopeptides (usage thérapeutique)</term><term>Ribavirine (effets indésirables)</term><term>Ribavirine (usage thérapeutique)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Thiazoles (effets indésirables)</term><term>Thiazoles (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Acrylates</term><term>Antiviral Agents</term><term>Benzimidazoles</term><term>Oligopeptides</term><term>Ribavirin</term><term>Thiazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acrylates</term><term>Antiviral Agents</term><term>Benzimidazoles</term><term>Oligopeptides</term><term>Ribavirin</term><term>Thiazoles</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Hepatitis C, Chronic</term><term>Liver Cirrhosis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis C, Chronic</term><term>Liver Cirrhosis</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Acrylates</term><term>Antiviraux</term><term>Benzimidazoles</term><term>Oligopeptides</term><term>Ribavirine</term><term>Thiazoles</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Cirrhose du foie</term><term>Hépatite C chronique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acrylates</term><term>Antiviraux</term><term>Benzimidazoles</term><term>Oligopeptides</term><term>Ribavirine</term><term>Thiazoles</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Cirrhose du foie</term><term>Femelle</term><term>Humains</term><term>Hépatite C chronique</term><term>Jeune adulte</term><term>Mâle</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with advanced hepatic fibrosis or cirrhosis with chronic hepatitis C virus (HCV) infection represent an unmet need. The HCV NS3/4A inhibitor, faldaprevir, was evaluated in combination with the nonnucleoside NS5B inhibitor, deleobuvir, with or without ribavirin in treatment-naive patients with HCV genotype 1 infection in the SOUND-C2 study. Here, the efficacy and safety of this interferon-free regimen in a subset of patients with advanced liver fibrosis, including those with compensated cirrhosis, were assessed. Patients (n=362) were randomized to once-daily faldaprevir with either twice-daily (BID) or three-times-daily (TID) deleobuvir for 16 (TID16W), 28 (TID28W and BID28W), or 40 (TID40W) weeks with or without ribavirin (TID28W-NR). Patients were classified according to fibrosis stage (F0 to F2 versus F3 to F4) and the presence of cirrhosis (yes/no). In total, 85 (24%) patients had advanced fibrosis/cirrhosis (F3 to F4) and 33 (9%) had cirrhosis. Within each treatment arm, differences in rates of sustained virologic response 12 weeks after completion of treatment (SVR12) between patients with mild to moderate fibrosis (F0 to F2) versus F3 to F4 did not show a consistent pattern and were not statistically significant (63% versus 47% for TID16W, 53% versus 76% for TID28W, 48% versus 67% for TID40W, 70% versus 67% for BID28W, and 40% versus 36% for TID28W-NR, respectively; P > 0.05 for each arm). The most frequent adverse events in patients with/without cirrhosis were gastrointestinal and skin events, which were mostly mild or moderate in intensity. The degree of liver fibrosis did not appear to affect the probability of achieving SVR12 following treatment with the interferon-free regimen of faldaprevir, deleobuvir, and ribavirin. (This study has been registered at ClinicalTrials.gov under registration no. NCT01132313.).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25512403</PMID><DateCreated><Year>2015</Year><Month>01</Month><Day>28</Day></DateCreated><DateCompleted><Year>2015</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.</ArticleTitle><Pagination><MedlinePgn>1282-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.04383-14</ELocationID><Abstract><AbstractText>Patients with advanced hepatic fibrosis or cirrhosis with chronic hepatitis C virus (HCV) infection represent an unmet need. The HCV NS3/4A inhibitor, faldaprevir, was evaluated in combination with the nonnucleoside NS5B inhibitor, deleobuvir, with or without ribavirin in treatment-naive patients with HCV genotype 1 infection in the SOUND-C2 study. Here, the efficacy and safety of this interferon-free regimen in a subset of patients with advanced liver fibrosis, including those with compensated cirrhosis, were assessed. Patients (n=362) were randomized to once-daily faldaprevir with either twice-daily (BID) or three-times-daily (TID) deleobuvir for 16 (TID16W), 28 (TID28W and BID28W), or 40 (TID40W) weeks with or without ribavirin (TID28W-NR). Patients were classified according to fibrosis stage (F0 to F2 versus F3 to F4) and the presence of cirrhosis (yes/no). In total, 85 (24%) patients had advanced fibrosis/cirrhosis (F3 to F4) and 33 (9%) had cirrhosis. Within each treatment arm, differences in rates of sustained virologic response 12 weeks after completion of treatment (SVR12) between patients with mild to moderate fibrosis (F0 to F2) versus F3 to F4 did not show a consistent pattern and were not statistically significant (63% versus 47% for TID16W, 53% versus 76% for TID28W, 48% versus 67% for TID40W, 70% versus 67% for BID28W, and 40% versus 36% for TID28W-NR, respectively; P > 0.05 for each arm). The most frequent adverse events in patients with/without cirrhosis were gastrointestinal and skin events, which were mostly mild or moderate in intensity. The degree of liver fibrosis did not appear to affect the probability of achieving SVR12 following treatment with the interferon-free regimen of faldaprevir, deleobuvir, and ribavirin. (This study has been registered at ClinicalTrials.gov under registration no. NCT01132313.).</AbstractText><CopyrightInformation>Copyright © 2015, American Society for Microbiology. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zeuzem</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>J. W. Goethe University Hospital, Frankfurt, Germany zeuzem@em.uni-frankfurt.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soriano</LastName><ForeName>Vicente</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Hospital Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asselah</LastName><ForeName>Tarik</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Service d'Hépatologie, Hôpital Beaujon, INSERM UMR S 1149, CRI, Université Paris Diderot, DHU UNITY, Clichy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gane</LastName><ForeName>Edward J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Auckland Clinical Studies, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bronowicki</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>INSERM 954, Centre Hospitalier Universitaire de Nancy, Vandoeuvre les Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angus</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Austin Health, Heidelberg, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lohse</LastName><ForeName>Ansgar W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>University Hospital Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stickel</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Müllhaupt</LastName><ForeName>Beat</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University Hospital of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Alfred Hospital, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuchmann</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Hospital Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manns</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical School of Hannover, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourlière</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hôpital Saint Joseph, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buti</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Jerry O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallivan</LastName><ForeName>John-Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabo</LastName><ForeName>John P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Böcher</LastName><ForeName>Wulf</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mensa</LastName><ForeName>Federico J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>SOUND-C2 Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01132313</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000179">Acrylates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C552340">N-((cyclopentyloxy)carbonyl)-3-methylvalyl-4-((8-bromo-7-methoxy-2-(2-((2-methylpropanoyl)amino)-1,3-thiazol-4-yl)quinolin-4-yl)oxy)-N-(1-carboxy-2-ethenylcyclopropyl)prolinamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>58BU988K90</RegistryNumber><NameOfSubstance UI="C000592437">deleobuvir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2010 Nov;54(11):4611-8</RefSource><PMID Version="1">20823284</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Aliment Pharmacol Ther. 2010 Aug;32(3):344-55</RefSource><PMID Version="1">20497143</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Mar 31;364(13):1207-17</RefSource><PMID Version="1">21449784</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2011 Jun;54(6):1114-22</RefSource><PMID Version="1">21145839</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2011 Aug;54(2):396-405</RefSource><PMID Version="1">21520194</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2011 Oct;54(4):1433-44</RefSource><PMID Version="1">21898493</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Liver Int. 2012 Feb;32 Suppl 1:2-8</RefSource><PMID Version="1">22212565</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2013 Mar;58(3):479-87</RefSource><PMID Version="1">23183529</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 May 16;368(20):1878-87</RefSource><PMID Version="1">23607594</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Aug 15;369(7):630-9</RefSource><PMID Version="1">23944300</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2013 Sep;59(3):434-41</RefSource><PMID Version="1">23669289</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 May 15;370(20):1889-98</RefSource><PMID Version="1">24725239</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 May 22;370(21):1973-82</RefSource><PMID Version="1">24725237</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2014 Aug 2;384(9941):414-26</RefSource><PMID Version="1">24907224</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2014 Aug 2;384(9941):403-13</RefSource><PMID Version="1">24907225</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pharmacol Exp Ther. 2014 Nov;351(2):403-12</RefSource><PMID Version="1">25204339</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Liver Int. 2015 Feb;35(2):417-21</RefSource><PMID Version="1">25263751</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2007 Mar;45(3):579-87</RefSource><PMID Version="1">17326216</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Aliment Pharmacol Ther. 2008 Apr 1;27(7):542-51</RefSource><PMID Version="1">18208570</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2009 Apr;49(4):1335-74</RefSource><PMID Version="1">19330875</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2009;14(4):577-84</RefSource><PMID Version="1">19578243</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2010 Feb;51(2):388-97</RefSource><PMID Version="1">19918980</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Liver Transpl. 2010 Jun;16(6):748-59</RefSource><PMID Version="1">20517909</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Mar 31;364(13):1195-206</RefSource><PMID Version="1">21449783</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000179" MajorTopicYN="N">Acrylates</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4335863</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25512403</ArticleId><ArticleId IdType="pii">AAC.04383-14</ArticleId><ArticleId IdType="doi">10.1128/AAC.04383-14</ArticleId><ArticleId IdType="pmc">PMC4335863</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F42 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002F42 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25512403
|texte= Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25512403" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |